Cargando…

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I

Enzyme replacement therapy (ERT) can produce anti-drug antibody (ADA) responses that reduce efficacy or lead to hypersensitivity reactions. Six patients with severe mucopolysaccharidosis type I (MPS I/Hurler syndrome) who did not receive hematopoietic stem cell transplantation underwent an immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giugliani, Roberto, Vieira, Taiane Alves, Carvalho, Clarissa Gutierrez, Muñoz-Rojas, Maria-Veronica, Semyachkina, Alla N., Voinova, Victoria Y., Richards, Susan, Cox, Gerald F., Xue, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238455/ https://www.ncbi.nlm.nih.gov/pubmed/28119821 http://dx.doi.org/10.1016/j.ymgmr.2017.01.004

Ejemplares similares

The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis()
por: Dualibi, Ana Paula Fiuza Funicello, et al.
Publicado: (2015)

Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series
por: Horovitz, Dafne Dain Gandelman, et al.
Publicado: (2016)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2017)

Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I
por: Dickson, P.I., et al.
Publicado: (2015)

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
por: Hsu, Yu-Hone, et al.
Publicado: (2017)

Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I
por: Wilson, Amanda, et al.
Publicado: (2021)

Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia
por: Voskoboeva, Elena, et al.
Publicado: (2022)

Analysis of long-term observations of the large group of Russian patients with Hunter syndrome (mucopolysaccharidosis type II)
por: Semyachkina, Alla Nikolaevna, et al.
Publicado: (2021)

Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes
por: Lund, Troy C., et al.
Publicado: (2019)

Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation
por: Polgreen, Lynda E., et al.
Publicado: (2019)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Bone Growth Induction in Mucopolysaccharidosis IVA Mouse
por: Rintz, Estera, et al.
Publicado: (2023)

CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE
por: Kyosen, Sandra Obikawa, et al.
Publicado: (2019)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2022)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
por: Giugliani, Roberto, et al.
Publicado: (2021)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I
por: Thomas, Janet A., et al.
Publicado: (2010)

Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting
por: Toscano, Antonio, et al.
Publicado: (2022)

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
por: Braunlin, Elizabeth A., et al.
Publicado: (2011)

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships
por: Al-Sannaa, Nouriya A., et al.
Publicado: (2015)

Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review
por: Pinto, Louise LC, et al.
Publicado: (2010)

Mucopolysaccharidosis Type I in the Russian Federation and Other Republics of the Former Soviet Union: Molecular Genetic Analysis and Epidemiology
por: Voskoboeva, E. Yu, et al.
Publicado: (2022)

Immunological evaluation of patients with mucopolysaccharidosis (MPS)
por: Aranda, Carolina, et al.
Publicado: (2015)

Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world
por: Muñoz-Rojas, María Verónica, et al.
Publicado: (2011)

Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights
por: Martins, Ana Maria, et al.
Publicado: (2018)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl
por: Semyachkina, A. N., et al.
Publicado: (2019)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity
por: Shams, Sedigheh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_17hma36fu6uvvndat604sr0igk